CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Forticell Bioscience, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Forticell Bioscience, Inc.
Suite 101,
333 Sylvan Avenue
Phone: (212) 740-6920p:212 740-6920 ENGLEWOOD CLIFFS, NJ  07632  United States Ticker: FORBQFORBQ
On 5/31/2013, the U.S. Securities and Exchange Commission revoked the registration of each class of registered securities of Forticell Bioscience, Inc. for failure to make required periodic filings with the Commission.
This company is no longer actively traded on any major stock exchange.
Business Summary
Forticell Bioscience, Inc. (Forticell), formerly Ortec International, Inc., is a development stage tissue engineering company with capabilities in cell culturing, biology and biomaterials. The Company has developed a product called OrCel (ORCEL), which is used to stimulate the repair and regeneration of human skin. ORCEL is a two-layered tissue engineered dressing that consists of human derived skin cells, both dermal and epidermal, supported within a porous collagen matrix. Its primary target patient populations for the use of ORCEL are persons with venous stasis and diabetic foot ulcers.
(Source: 10KSB)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/200812/31/2007YesYesYes--

Industries
SIC Code Description
8071 Medical laboratories

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board Shepard M.Goldberg 53 9/17/2008 6/29/2007
Acting Chief Executive Officer, Chief Financial Officer, Secretary, Director Alan W.Schoenbart 49 9/17/2008 12/29/2004

Business Names
Business Name
FORBQ
Forticell Bioscience, Inc.
Ortec International Inc.
Ortec International, Inc.

General Information
Number of Employees: 20 (As of 12/31/2007)
Outstanding Shares: 13,366,130 (As of 10/31/2008)
Shareholders: 1,450
Stock Exchange: OTC
Federal Tax Id: 113068704
Fax Number: (212) 740-2570
Email Address: ortecinfo@aol.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, July 21, 2023